Inhibrx Stock (NASDAQ:INBX), Quotes and News Summary

Q: What sector and industry does Inhibrx (INBX) operate in?

Inhibrx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Inhibrx Stock (NASDAQ: INBX) stock price, news, charts, stock research, profile.

Open	$34.170
Close	$34.090
Volume / Avg.	179.063K / 529.785K
Day Range	34.020 - 34.220
52 Wk Range	14.305 - 39.790
Market Cap	$1.616B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	35
Short Interest	6.95%
Days to Cover	6.05

Recent News

French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B

Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.

Vandana Singh

Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project

Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO.

Benzinga Neuro

$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trend

Nov 23

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About Inhibrx Inc

Sector

Health Care

Industry

Biotechnology

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biol...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Inhibrx (INBX) stock?

You can purchase shares of Inhibrx (NASDAQ: INBX) through any online brokerage.

View our list of the best stock brokerages.

Who are Inhibrx's (INBX) competitors?

Other companies in Inhibrx’s space includes: Twist Bioscience (NASDAQ:TWST), Gyre Therapeutics (NASDAQ:GYRE), Syndax Pharmaceuticals (NASDAQ:SNDX), Fusion Pharmaceuticals (NASDAQ:FUSN) and Day One Biopharmaceutical (NASDAQ:DAWN).

What is the target price for Inhibrx (INBX) stock?

The latest price target for Inhibrx (NASDAQ: INBX) was reported by JMP Securities on Tuesday, January 23, 2024. The analyst firm set a price target for 0.00 expecting INBX to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

Current Stock Price for Inhibrx (INBX)?

The stock price for Inhibrx (NASDAQ: INBX) is $34.09 last updated April 25, 2024 at 4:20 PM EDT.

Does Inhibrx (INBX) pay a dividend?

There are no upcoming dividends for Inhibrx.

When is Inhibrx (NASDAQ:INBX) reporting earnings?

Inhibrx’s Q1 earnings are confirmed for Monday, May 6, 2024.

Is Inhibrx (INBX) going to split?

There is no upcoming split for Inhibrx.

What sector and industry does Inhibrx (INBX) operate in?

Inhibrx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-